Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 7/20 | 0.66 |
| ▸ | KMT2A | Q03164 | 7/20 | 0.66 |
| ▸ | MAPT | P10636 | 6/20 | 0.66 |
| ▸ | NPC1 | O15118 | 4/20 | 0.66 |
| ▸ | RAB9A | P51151 | 4/20 | 0.66 |
| ▸ | NFKB1 | P19838 | 2/20 | 0.66 |
| ▸ | NFKB2 | Q00653 | 2/20 | 0.66 |
| ▸ | RELA | Q04206 | 2/20 | 0.66 |
| ▸ | CSNK2A2 | P19784 | 1/20 | 0.66 |
| ▸ | RECQL | P46063 | 1/20 | 0.66 |
| ▸ | CSNK2B | P67870 | 1/20 | 0.66 |
| ▸ | CSNK2A1 | P68400 | 1/20 | 0.66 |
| ▸ | CYP3A4 | P08684 | 7/20 | 0.64 |
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.64 |
| ▸ | TP53 | P04637 | 6/20 | 0.64 |
| ▸ | CYP2C9 | P11712 | 4/20 | 0.64 |
| ▸ | CYP2C19 | P33261 | 4/20 | 0.64 |
| ▸ | MAOB | P27338 | 4/20 | 0.64 |
| ▸ | CYP1A1 | P04798 | 4/20 | 0.64 |
| ▸ | CYP1A2 | P05177 | 4/20 | 0.64 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10305796 | 0.86 | TERT (0.66) | MEN1KMT2AMAPTNPC1RAB9A | |
| SCHEMBL10305800 | 0.81 | AKR1B1 (0.64) | MAPTCSNK2A2RECQLCSNK2BCSNK2A1 | |
| SCHEMBL6614508 | 0.81 | TERT (0.73) | MEN1KMT2AMAPTNPC1RAB9A | |
| SCHEMBL6618581 | 0.80 | TUBB4A (0.67) | MEN1KMT2AMAPTNPC1RAB9A | |
| SCHEMBL490928 | 0.80 | MAPT (1.00) | MEN1KMT2AMAPTNPC1RAB9A | |
| SCHEMBL13355967 | 0.80 | CYP1A1 (0.70) | MEN1KMT2AMAPTNPC1RAB9A | |
| SCHEMBL31675989 | 0.80 | MAPT (1.00) | MEN1KMT2AMAPTNPC1RAB9A | |
| Acacetin SCHEMBL29387049 | 0.78 | CYP1B1 (1.00) | MEN1KMT2AMAPTNPC1RAB9A | |
| Acacetin SCHEMBL107712 | 0.78 | CYP1B1 (1.00) | MEN1KMT2AMAPTNPC1RAB9A | |
| Acacetin SCHEMBL28278297 | 0.77 | CYP1B1 (0.97) | MEN1KMT2AMAPTNPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8293315-B2 | Process for the preparation of active substance concentrate | COGNIS IP MANAGEMENT GMBH (DE) | 2012-10-23 | — | — | US | disclosed |
| US-8293315-B2 | Process for the preparation of active substance concentrate | COGNIS IP MANAGEMENT GMBH (DE) | 2012-10-23 | — | — | US | disclosed |
| EP-1738738-B1 | Microcapsules | COGNIS IP MAN GMBH (DE) | 2012-07-11 | — | — | EP | disclosed |
| EP-2060251-B1 | Method for manufacturing active agent concentrates | COGNIS IP MAN GMBH (DE) | 2011-03-23 | — | — | EP | disclosed |
| EP-1600061-B1 | Oral and/or topical compositions | COGNIS IP MAN GMBH (DE) | 2010-05-12 | — | — | EP | disclosed |
| US-20100009063-A1 | Process for the preparation of active substance concentrate | COGNIS IP MANAGEMENT GMBH (DE) | 2010-01-14 | — | — | US | disclosed |
| US-20100009063-A1 | Process for the preparation of active substance concentrate | COGNIS IP MANAGEMENT GMBH (DE) | 2010-01-14 | — | — | US | disclosed |
| EP-2060251-A1 | Method for manufacturing active agent concentrates | Cognis IP Management GmbH (DE) | 2009-05-20 | — | — | EP | disclosed |
| EP-1623757-B1 | Microcapsules (XXXII) | COGNIS IP MAN GMBH (DE) | 2009-02-11 | — | — | EP | disclosed |
| US-20080268024-A1 | Compositions for Oral and/or Topical Administration | COGNIS IP MANAGEMENT GMBH (DE) | 2008-10-30 | — | — | US | disclosed |
| US-20080268024-A1 | Compositions for Oral and/or Topical Administration | COGNIS IP MANAGEMENT GMBH (DE) | 2008-10-30 | — | — | US | disclosed |
| US-20080220101-A1 | COMPOSITIONS OF EXTRACTS OF ALOE FOR ORAL ADMINISTRATION | COGNIS IP MANAGEMENT GMBH (DE) | 2008-09-11 | — | — | US | disclosed |
| US-20080220101-A1 | COMPOSITIONS OF EXTRACTS OF ALOE FOR ORAL ADMINISTRATION | COGNIS IP MANAGEMENT GMBH (DE) | 2008-09-11 | — | — | US | disclosed |
| EP-1967197-A1 | Use of preparations, purifications and extracts of aloe | Cognis IP Management GmbH (DE) | 2008-09-10 | — | — | EP | disclosed |
| WO-2008046521-A1 | PREPARATION FOR ORAL ADMINISTRATION (II) | COGNIS IP MANAGEMENT GMBH (DE) | 2008-04-24 | — | — | WO | disclosed |
| WO-2008028585-A2 | COSMETIC AND/OR PHARMACEUTICAL PREPARATIONS CONTAINING HOODIA EXTRACTS | COGNIS IP MANAGEMENT GMBH (DE) | 2008-03-13 | — | — | WO | disclosed |
| WO-2008028584-A1 | PREPARATIONS FOR ORAL ADMINISTRATION (I) | COGNIS IP MANAGEMENT GMBH (DE) | 2008-03-13 | — | — | WO | disclosed |
| WO-2007068390-A1 | PRE-MIXES FOR PERSONAL AND HOME CARE COMPOSITIONS | COGNIS IP MANAGEMENT GMBH (DE) | 2007-06-21 | — | — | WO | disclosed |
| EP-1798279-A1 | Pre-mixes for personal and home care compositions | Cognis IP Management GmbH (DE) | 2007-06-20 | — | — | EP | disclosed |
| EP-1738738-A1 | Microcapsules | Cognis IP Management GmbH (DE) | 2007-01-03 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080268024-A1 | Compositions for Oral and/or Topical Administration | FABP2, FABP6, CUTA | MEN1 2644/4885KMT2A 4465/4885MAPT 184/4885 |
| US-20080220101-A1 | COMPOSITIONS OF EXTRACTS OF ALOE FOR ORAL ADMINISTRATION | LIPE, ALOX15, ALOX5 | MEN1 1604/4885KMT2A 3788/4885MAPT 4750/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.